Colorectal Cancer Clinical Trials in Atlanta

Showing 121-140 of 283 trials

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

NCT03368963

This phase I/II trial studies the best dose and how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have spread to other places in the body (metastatic) or cannot be removed by surgery. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102 and nanoliposomal irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Colorectal AdenocarcinomaGastric AdenocarcinomaMetastatic Pancreatic Adenocarcinoma+11 more

Emory University64 participantsStarted Jan 2018

Atlanta, Georgia, United States • Atlanta, Georgia, United States • Atlanta, Georgia, United States

Approved For Marketing< 1 mile

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

NCT02286492

The objective of the program is to provide access to TAS-102 to patients with metastatic colorectal cancer who are refractory to or failing standard chemotherapy, are new to therapy with TAS-102 and in whom therapy with TAS-102 is clinically indicated.

Colorectal Cancer Metastatic

Taiho Oncology, Inc.

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Fresno, California, United States +30 more locations

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Colorectal Cancer Trials in Other Cities

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Comparative Effectiveness of FITs With Colonoscopy

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

Other Conditions in Atlanta